Immunome, Inc. (NASDAQ:IMNM) Short Interest Update

Immunome, Inc. (NASDAQ:IMNM) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 9,070,000 shares, a decrease of 13.9% from the January 15th total of 10,540,000 shares. Currently, 13.0% of the shares of the company are sold short. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is currently 9.1 days.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on IMNM shares. Piper Sandler reduced their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Stephens initiated coverage on Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Immunome in a report on Monday, January 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $28.60.

Immunome Trading Down 0.3 %

Shares of NASDAQ IMNM opened at $10.40 on Tuesday. The stock has a fifty day simple moving average of $10.83 and a two-hundred day simple moving average of $12.38. Immunome has a 1-year low of $8.97 and a 1-year high of $30.96. The firm has a market cap of $829.71 million, a price-to-earnings ratio of -1.28 and a beta of 1.90.

Insider Activity

In other Immunome news, CEO Clay B. Siegall bought 66,057 shares of Immunome stock in a transaction dated Thursday, November 21st. The stock was bought at an average cost of $9.54 per share, with a total value of $630,183.78. Following the completion of the acquisition, the chief executive officer now directly owns 485,693 shares in the company, valued at approximately $4,633,511.22. The trade was a 15.74 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CTO Philip Tsai bought 21,000 shares of Immunome stock in a transaction dated Thursday, November 21st. The stock was acquired at an average cost of $9.43 per share, with a total value of $198,030.00. Following the completion of the acquisition, the chief technology officer now owns 21,000 shares of the company’s stock, valued at $198,030. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 252,862 shares of company stock valued at $2,140,545 over the last three months. Corporate insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in shares of Immunome in the fourth quarter worth $70,000. KLP Kapitalforvaltning AS bought a new position in shares of Immunome in the fourth quarter worth $75,000. AlphaQuest LLC boosted its holdings in shares of Immunome by 786,700.0% in the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after acquiring an additional 7,867 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after acquiring an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC bought a new position in shares of Immunome in the fourth quarter worth $95,000. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.